We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

321 hedge funds and large institutions have $8.94B invested in BioMarin Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 128 increasing their positions, 103 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more call options, than puts

Call options by funds: $140M | Put options by funds: $100M

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

25% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 36

24% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 103

3% more funds holding

Funds holding: 313 → 321 (+8)

14% less capital invested

Capital invested by funds: $10.4B → $8.94B (-$1.45B)

Holders
321
Holders Change
+8
Holders Change %
+2.56%
% of All Funds
9.23%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.32%
New
45
Increased
128
Reduced
103
Closed
36
Calls
$140M
Puts
$100M
Net Calls
+$40.2M
Net Calls Change
+$53.1M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$132M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$116M
3
Millennium Management
Millennium Management
New York
+$82M
4
Norges Bank
Norges Bank
Norway
+$67.5M
5
WRF
Waddell & Reed Financial
Kansas
+$35.7M

Top Sellers

1
Winslow Capital Management
Winslow Capital Management
Minnesota
-$291M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$177M
3
Jennison Associates
Jennison Associates
New York
-$161M
4
Capital World Investors
Capital World Investors
California
-$76.4M
5
HCM
Holland Capital Management
Illinois
-$53.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
Sectoral Asset Management
Quebec, Canada
$72.7M +$14.6M +241,098 +26%
CWAM
27
Columbia Wanger Asset Management
Illinois
$72.6M -$13.4M -221,200 -16%
BG
28
BlackRock Group
United Kingdom
$72.1M -$7.24M -119,889 -9%
UBS AM
29
UBS AM
Illinois
$69.8M +$597K +9,881 +0.9%
GGHC
30
Gilder Gagnon Howe & Co
New York
$68.5M -$235K -3,886 -0.4%
CS
31
Credit Suisse
Switzerland
$68.2M +$32.2M +533,722 +95%
BA
32
BlackRock Advisors
Delaware
$65.9M -$9.42M -155,936 -13%
Deutsche Bank
33
Deutsche Bank
Germany
$64.2M +$7.64M +126,504 +14%
Northern Trust
34
Northern Trust
Illinois
$63.5M -$26M -430,486 -30%
Goldman Sachs
35
Goldman Sachs
New York
$59.6M +$21.8M +360,399 +60%
First Trust Advisors
36
First Trust Advisors
Illinois
$58.9M +$2.17M +35,990 +4%
PAI
37
Palo Alto Investors
California
$57M +$10.3M +169,900 +23%
MAA
38
Managed Account Advisors
New Jersey
$53.6M -$28.9M -477,643 -36%
CCI
39
Columbus Circle Investors
$53.5M +$13.2M +218,447 +34%
JP Morgan Chase
40
JP Morgan Chase
New York
$53.4M -$3.98M -65,828 -7%
JCP
41
Jabre Capital Partners
Switzerland
$50.2M +$32.7M +540,855 +204%
ClearBridge Investments
42
ClearBridge Investments
New York
$47.7M -$261K -4,323 -0.6%
Geode Capital Management
43
Geode Capital Management
Massachusetts
$46.2M +$1.31M +21,678 +3%
HCM
44
Holland Capital Management
Illinois
$46.2M -$53.2M -880,514 -54%
UIM
45
USS Investment Management
United Kingdom
$46M – – –
TCIM
46
TIAA CREF Investment Management
New York
$42.1M +$11.2M +185,815 +38%
American Century Companies
47
American Century Companies
Missouri
$38.8M -$13.2M -218,100 -26%
Bank of America
48
Bank of America
North Carolina
$38.2M +$3.89M +64,362 +12%
Fidelity International
49
Fidelity International
Bermuda
$37.8M +$7.66M +126,871 +26%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$37.8M +$324K +5,371 +0.9%
1
2
3 4 5

BMRN Hedge Fund Activity: Q2 2014 in Review

321 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2014, worth a combined $8.94B — down 14% from $10.4B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new BMRN positions and 36 closed out — a net gain of 9 holders — while 128 added to existing stakes and 103 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $132M. The largest seller was Winslow Capital Management, cutting an estimated $291M.

  • 321 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2014, up from 313 in Q1 2014.
  • Funds reported $8.94B of BioMarin Pharmaceuticals stock for Q2 2014, down 14% quarter-over-quarter.
  • 45 funds opened new BioMarin Pharmaceuticals positions in Q2 2014 and 36 closed out, a net change of +9 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q2 2014 was Sands Capital Management, an estimated $132M added.
  • The largest BioMarin Pharmaceuticals seller in Q2 2014 was Winslow Capital Management, an estimated $291M sold.

Based on aggregated 13F filings for Q2 2014.